Clinical trial
ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
NCT00011037 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00011037 |
|---|---|
| Title | ALVAC-HIV vCP1452 Alone and Combined With MN rgp120 |
| Official title | A Multisite Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of ALVAC-HIV vCP1452 Alone and Combined With MN rgp120 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | ALVAC(2)120(B, MN)GNP (vCP1452), MN rgp120/HIV-1, MN)GNP (vCP1452) placebo, MN rgp120/HIV-1 placebo |
| Enrollment | 160 |
| Completion | Jul 1, 2004 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 14, 2021 |
| Countries | Brazil, Haiti, Peru, Trinidad and Tobago |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: